Comparative Study Ticagrelor Novel Antiplatelet Drug and Aspirin in Secondary Prevention Cerebral Infarction/YANG Wei， LI Ping， WU Youhao， FAN Wenfeng， WANG Tianzhong. //Medical Innovation China， 2025，22(12)： 001-005

    [Abstract]Objective： To explore the effct Ticagrelor novelantiplateletdrug and Aspirin in secondary prevention cerebralinfarction.Method：A total 124 patients withcerebral infarction admitted to ， Zhongxiang People's Hospital from March 2020 to January 2022 were selected and divided into experimental group ( n =62) and control group (n=62) according to random envelope method. The control group was treated with Aspirin，and the experimental group was treated witha novelantiplatelet drug Ticagrelor.Cognition and limb function， platelet aggregation rate，cerebral bloodperfusion parameters and recurrence were compared between the two groups.Result： After 6 months treatment， the scores mini-mental state examination (MMSE) and Fugl-Meyer assessment (FMA)increased inbothgroups，theplatelet aggregationrateatland5mindecreased， and the scores MMSEandFMA inthe experimental groupwerehigher than those inthecontrol group ......